Probiotics in the restoration of normal vaginal microbiocenosis and prevention of bacterial infections recurrent


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Probiotic products containing L. rhamnosus GR-1 and L. reuteri RC-14 - the types most often found in healthy women in the intestines and urinary tract - are most effective for restoring the microbiocenosis of the vagina when taken for 1-1,5 months and preventing the recurrence of bacterial vaginosis and vulvovaginal candidiasis. Currently available data indicate that certain strains of lactobacilli, administered intravaginally, are also able to colonize the vagina, but require further study.

Full Text

Restricted Access

About the authors

G. B Dikke

Academy of Medical Education n.a. F.I. Inozemtsev

Email: galadikke@yandex.ru
MD, Associate Professor, Professor of the Department of Obstetrics and Gynecology with a course of reproductive medicine 22, letter M, Moscow Avenue, St. Petersburg 190013, Russian Federation

References

  1. Мелкумян А.Р., Припутневич Т.В., Анкирская А.С. и др. Видовой состав лактобактерий при различном состоянии микробиоты влагалища у беременных. Клиническая микробиологическая антимикробная химиотерапия. 2013;15(1):72-9
  2. Демкин В.В. Видовое разнообразие лактобактерий вагинального микробиома: как посмотреть. Молекулярная генетика, микробиология и вирусология. 2018;36(3):3-12. Doi: 10.17116/ molgen2018360313
  3. Ravel J, Gajer P, Abdo Z., et al. Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. USA. 2011;15( 108, Suppl. 1):4680-87. doi: 10.1073/pnas.W02611W7.
  4. Прилепская В.Н., Байрамова Г.Р. Вульвовагинальный кандидоз. Клиника, диагностика, принципы терапии. М., 2010. 80 c.
  5. Савичева А.М., Шалепо К.В., Назарова В.В., Менухова Ю.Н. Все ли лактобациллы одинаково полезны? Полнота восстановления вагинальной микроэкологии как критерий эффективности двухэтапной терапии бактериального вагиноза. Status Praesens. Акушерство, гинекология, бесплодный брак. 2014;3(20):33-7
  6. Ворошилина Е.С., Плотко Е.Э., Хаютин Л.В. и др. Преобладание Lactobacillus iners в микробиоценозе влагалища женщин с умеренным дисбиозом ассоциировано с наличием клинических признаков инфекционно-воспалительной патологии влагалища. Вестник РГМУ. 2017;2:47-51
  7. Будиловская О.В., Шипицына Е.В., Герасимова Е.Н. и др. Видовое разнообразие вагинальных лактобацилл в норме и при дисбиотических состояниях. Журнал акушерства и женских болезней. 2017;66(2):24-32. Doi: 10.17816/ JOWD66224-32
  8. Меджидова М.К., Зайдиева З.С., Вересова А.А. Микробиоценоз влагалища и факторы, влияющие на его состояние. Медицинский совет. 2013;3-2:118-25. doi: 10.21518/2079-701X-2013-3-2-118-125
  9. Кира Е.Ф. Бактериальный вагиноз. М., 2012. 472 с. [Kira E.F. Bacterial vaginosis. M., 2012. 472
  10. Petersen C., Round J.L. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014;16:1024-33. Doi: 10.1111/ cmi.12308.
  11. Хрянин А.А., Решетников О.В. Бактериальный вагиноз. Новые представленияомикробном биосоциуме и возможности лечения. Медицинский совет. 2014;17:128-32.
  12. Schippa S., Conte M.P Dysbiotic Events in Gut Microbiota: Impact on Human Health. Nutrients. 2014;6:5786-805. doi: 10.3390/nu6125786.
  13. Gagliardi A., Totino V, Cacciotti F, et al. Rebuilding the Gut Microbiota Ecosystem. Int J Environ Res Public Health. 2018;15(8):1679. Doi: 10.3390/ ijerph15081679.
  14. Lau K., Srivatsav V., Rizwan A., et al. Bridging the gap between gut microbial dysbiosis and cardiovascular diseases. Nutrients. 2017;9(8):859. doi: 10.3390/nu9080859.
  15. DeGruttola A.K., Low D., Mizoguchi A., Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016;22(5):1137-50. Doi: 10.1097/ MIB.0000000000000750.
  16. Horta-Baas G., Romero-Figueroa M.D.S., Montiel-Jarqufn A.J., et al. Intestinal Dysbiosis and Rheumatoid Arthritis: A Link between gut microbiota and the pathogenesis of rheumatoid arthritis. J Immunol Res. 2017;2017:4835189. doi: 10.1155/2017/4835189.
  17. Clemente J.C., Ursell L.K., Parfrey L.W., Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148(6):1258-70. doi: 10.1016/j.cell.2012.01.035.
  18. Freitas A.C., Hill J.E. Bifidobacteria isolated from vaginal and gut microbiomes are indistinguishable by comparative genomics. PLoS One. 2018;13(4):e0196290. doi: 10.1371/joumaL pone.0196290.
  19. Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr issues intest Microbiol. 2001;2(2):43-53.
  20. Heeney D.D., Gareau M.G., Marco M.L. intestinal Lactobacillus in health and disease, a driver or just along for the ride? Curr Opin Biotechnol. 2018;49:140-7. Doi: 10.1016/j. copbio.2017.08.004.
  21. Федеральные клинические рекомендации по ведению больных бактериальным вагинозом. М, 2015. 15 с. [Federal clinical guidelines for management of patients with bacterial vaginosis. M., 2015. 15 p. (in Russ.)].
  22. Kechagia M., Basoulis D., Konstantopoulou S., et al. Health benefits of probiotics: a review. iSRN Nutr. 2013:481651. doi: 10.5402/2013/481651.
  23. Falagas M.E., Betsi G.i., Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol inf. 2007;13(7):657-64. doi: 10.1111/j.1469-0691.2007.01688.x.
  24. Senok A.C, Verstraelen H., Temmerman M., Botta G.A. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev. 2009;4:CD006289. doi: 10.1002/14651858. CD006289.pub2.
  25. Mastromarino P., Vitali B., Mosca L. Bacterial vaginosis: a review on clinical trials with probiotics. New Microbial. 2013;36:229-38.
  26. Homayouni A., Bastani P, Ziyadi S., et al. Effects of probiotics on the recurrence of bacterial vaginosis: a review. J Low Genit Tract Dis. 2014;18(1):79-86. doi: 10.1097/LGT.0b013e31829156ec.
  27. Segers M.E., Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG--host interactions. Microb Cell Fact. 2014;13(Suppl. 1):S7. doi: 10.1186/1475-2859-13-S1-S7.
  28. Reid G., Zalai C., Gardiner G. Urogenital lactobacilli probiotics, reliability and regulatory issues. J Dairy Sci. 2001;84(E. Suppl.):164-69.
  29. Bertuccini L., Russo R., iosi F, Superti F. Effects of Lactobacillus rhamnosus and Lactobacillus acidophilus on bacterial vaginal pathogens. int J immunopathol Pharmacol. 2017;30(2):163-67. doi: 10.1177/0394632017697987.
  30. Reid G. The development of probiotics for women's health. Canad J Microbiol. 2017;63(4):269-77. doi: 10.1139/cjm-2016-0733.
  31. Montalban-Arques A., De Schryver P, Bossier P, et al. Selective manipulation of the gut microbiota improves immune status in vertebrates. Front immunol. 2015;6:512. Doi: 10.3389/ fimmu.2015.00512.
  32. Yang S., Reid G., Challis J.R.G., et al. is there a role for probiotics in the prevention of preterm birth? Front immunol. 2015;6:62. Doi: 10.3389/ fimmu.2015.00062.
  33. Rodenas G.C.L., Lepage M., Ngom-Bru C., et al. Effect of formula containing Lactobacillus reuteri DSM 17938 on fecal microbiota of infants born by cesarean-section. J Pediatr Gastroenterol Nutr. 2016);63:681-87. Doi: 10.1097/ MPG.0000000000001198.
  34. Galley J.D., Mackos A.R., Varaljay V.A., Bailey M.T. Stressor exposure has prolonged effects on colonic microbial community structure in Citrobacter rodentium-challenged mice. Sci Rep. 2017;7:45012. doi: 10.1038/srep45012.
  35. Su Y., Chen X., Liu M., Guo X. Effect of three lactobacilli with strain-specific activities on the growth performance, faecal microbiota and ileum mucosa proteomics of piglets. J Anim Sci Biotechnol. 2017;8:52. doi: 10.1186/s40104-017-0183-3.
  36. Yang Y., Zhao X., Le M.H., et al. Reutericyclin producing Lactobacillus reuteri modulates development of fecal microbiota in weanling pigs. Front Microbiol. 2015;6:762. Doi: 10.3389/ fmicb.2015.00762.
  37. Reid G., Bruce E. Selection of lactobacillus strains used as probiotics for treatment urogenital diseases. J inf Dis. 2001;183(1):77-80. doi: 10.1086/318841.
  38. Reid G., Bruce A.W., Fraser N., et al. Oral probiotics can resolve urogenital infections. Pathog Dis. 2001;30(1):49-52. doi: 10.1111/j.1574-695X.2001.tb01549.x.
  39. Mu Q., Tavella V.J., Luo X.M. Role of Lactobacillus reuteri in Human Health and Diseases. Front Microbiol. 2018;9:75 7. Doi: 10.3389/ fmicb.2018.00757.
  40. Reid G., Charbonneau D., Erb J, et al. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS immunol Med Microbiol. 2003;35:131-34.
  41. Martinez R.C., Seney S.L., Summers K.L., et al. Effect of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the ability of Candida albicans to infect cells and induce inflammation. Microbiol immunol. 2009;53(9):487-95. doi: 10.1111/j.1348-0421.2009.00154.x.
  42. Morelli L., Zonenenschain D., Del Piano M., Cognein P. Utilization of the intestinal tract as a delivery system for urogenital probiotics. J Clin Gastroenterol. 2004;38:107-10.
  43. Reid G., Beuerman D., Heinemann C., Bruce A.W. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS immunol Med Microbiol. 2001;32:37-41.
  44. Gardiner G.E., Heinemann C., Bruce A.W., et al. Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR-1 but not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA. Clin Diagn Lab immunol. 2002;9(1):92-6. doi: 10.1128/CDLi.9.1.92-96.2002.
  45. Инструкция по медицинскому применению биологически активной добавки вагилак (vagilac), капсулы 230 мг № государственной регистрации: KZ 16.01.78.003.E.001538.08.14 от 06.08.2014. Энциклопедия РЛС. https:// www.rlsnet.ru/
  46. Vujic G. Efficacy of orally applied probiotic capsules for bacterial vaginosis and other vaginal infections: a double-blind, randomized, placebo-controlled study Goran. Eur J Obstet Gynecol Reprod Biol. 2013;168(1):75-9. Doi: 10.1016/j. ejogrb.2012.12.031.
  47. Anukam K., Osazuwa E., Ahonkhai i., et al. Augmentation of antimicrobial metronidazole therapy of bacterial vaginosis with oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14: randomized, double-blind, placebo controlled trial. Microbes infect. 2006; 8:1450-54.
  48. Радзинский В.Е., Ордиянц И.М., Апресян С.В. Эффективность коррекции дисбиоза влагалища в i триместре беременности. Российский вестник акушера-гинеколога. 2010;10(3):38-41.
  49. McMillan А., Dell M., Zellar M.P, Cribby S., et al. Disruption of urogenital biofilms by lactobacilli. Colloids Surf. B Biointerfaces. 2011;86:58-64. doi: 10.1016/j.colsurfb.2011.03.016.
  50. Menard J.P Antibacterial treatment of bacterial vaginosis: current and emerging therapies. int J Womens Health. 2011;3:295-305. doi: 10.2147/iJWH.S23814.
  51. Hummelen R., Changalucha J., Butamanya N.L., et al. Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 to prevent or cure bacterial vaginosis among women with HiV. int J Gynaecol Obstet. 2010;111(3):245-48. Doi: 10.1016/j. ijgo.2010.07.008.
  52. Cianci A., Giordano R., Delia A., et al. Efficacy of Lactobacillus Rhamnosus GR-1 and of Lactobacillus Reuteri RC-14 in the treatment and prevention of vaginoses and bacterial vaginitis relapses. Minerva Ginecol. 2008;60(5):369-76.
  53. Kohler G.A., Assefa S., Reid G. Probiotic interference of Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 with the opportunistic fungal pathogen Candida albicans. infect Dis Obstet Gynecol. 2012:636474. doi: 10.1155/2012/636474.
  54. Chew S.Y, Cheah Y.K., Seow H.F., et al. Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 exhibit strong antifungal effects against vulvovaginal candidiasis-causing Candida glabrata isolates. J Appl Microbiol. 2015;118(5):1180-90. Doi: 10.1111/ jam.12772.
  55. Ho M., Chang Y.Y., Chang W.C., et al. Oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 to reduce Group B Streptococcus colonization in pregnant women: A randomized controlled trial. Taiwan J Obstet Gynecol. 2016;55(4):515-18. Doi: 10.1016/j. tjog.2016.06.003.
  56. Евсеев А.А., Пивоварова О.Ю. Комплексная терапия бактериального вагиноза. Здоровье женщины. 2012;4(70):142-46.
  57. Новикова С.В., Логутова Л.С., Игнатьева М.А. Клиническая оценка эффективности и безопасности применения препарата вагилак для лечения бактериального вагиноза у беременных. Медицинский совет. 2018;13:90-4
  58. Кудинов С.В., Суховей Ю., Петров С.А. Эффективность коррекции дисбиоза влагалища пробиотиком вагилак перед радиохирургическим лечением у пациенток с эктопией шейки матки. Журнал акушерства и женских болезней. 2011;6:35-9

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies